PURPOSE: Erectile dysfunction is associated with all the common treatment options for prostate cancer. The aim of this research was to evaluate the relationship between erectile function and radiation dose to the penile bulb (PB) and other proximal penile structures in men receiving conformal radiotherapy (CRT) without hormonal therapy (HT) for prostate cancer, whose sexual function was known before treatment. PATIENTS AND METHODS: The study included 19 patients treated with 3D-CRT for localized prostate cancer at our department, who were self-reported to be potent before treatment, had not received HT, and had complete follow-up data available. Our evaluation was based on the International Index of Erectile Function (IIEF-5). Dose-volume histograms (DVHs) were used to evaluate the dose to the PB. Statistical analysis was performed with an unconditional logistic regression model. RESULTS: All patients reported change in potency after radiation. Eight patients (42%) remained potent but showed a decrease of 1 or 2 levels of potency, as defined by the IIEF-5 questionnaire (reduced potency group), while 11 patients (58%) reported a change of higher levels and revealed a severe erectile dysfunction after 2 years (impotence group). Multivariate analysis of morphological and dosimetric variables yielded significance for the mean dose (p = 0.05 with an odds ratio of 1.14 and 95% CI 1-1.30). Patients receiving a mean dose of less than 50 Gy to the PB appear to have a much greater likelihood of maintaining potency. CONCLUSION: Our data suggest a possible existence of a dose-volume correlation between the dose applied to the PB and radiation-induced impotence.
PURPOSE:Erectile dysfunction is associated with all the common treatment options for prostate cancer. The aim of this research was to evaluate the relationship between erectile function and radiation dose to the penile bulb (PB) and other proximal penile structures in men receiving conformal radiotherapy (CRT) without hormonal therapy (HT) for prostate cancer, whose sexual function was known before treatment. PATIENTS AND METHODS: The study included 19 patients treated with 3D-CRT for localized prostate cancer at our department, who were self-reported to be potent before treatment, had not received HT, and had complete follow-up data available. Our evaluation was based on the International Index of Erectile Function (IIEF-5). Dose-volume histograms (DVHs) were used to evaluate the dose to the PB. Statistical analysis was performed with an unconditional logistic regression model. RESULTS: All patients reported change in potency after radiation. Eight patients (42%) remained potent but showed a decrease of 1 or 2 levels of potency, as defined by the IIEF-5 questionnaire (reduced potency group), while 11 patients (58%) reported a change of higher levels and revealed a severe erectile dysfunction after 2 years (impotence group). Multivariate analysis of morphological and dosimetric variables yielded significance for the mean dose (p = 0.05 with an odds ratio of 1.14 and 95% CI 1-1.30). Patients receiving a mean dose of less than 50 Gy to the PB appear to have a much greater likelihood of maintaining potency. CONCLUSION: Our data suggest a possible existence of a dose-volume correlation between the dose applied to the PB and radiation-induced impotence.
Authors: Kent E Wallner; Gregory S Merrick; Mark L Benson; Wayne M Butler; Jeffrey Maki; Bryan G Tollenaar Journal: Int J Radiat Oncol Biol Phys Date: 2002-07-15 Impact factor: 7.038
Authors: M Roach; B Pickett; J Holland; K A Zapotowski; D L Marsh; B S Tatera Journal: Int J Radiat Oncol Biol Phys Date: 1993-01-15 Impact factor: 7.038
Authors: Michael Pinkawa; Marc D Piroth; Richard Holy; Victoria Djukic; Jens Klotz; Barbara Krenkel; Michael J Eble Journal: Strahlenther Onkol Date: 2011-07-25 Impact factor: 3.621
Authors: S Carrier; H Hricak; S S Lee; K Baba; D M Morgan; L Nunes; G Y Ross; T L Phillips; T F Lue Journal: Radiology Date: 1995-04 Impact factor: 11.105
Authors: R O Schiel; W Herzog; H Hof; J Debus; H-C Friederich; A Brechtel; J Rummel; P Freytag; M Hartmann Journal: Strahlenther Onkol Date: 2013-06-09 Impact factor: 3.621
Authors: William A Hall; Snehal Deshmukh; Deborah W Bruner; Jeff M Michalski; James A Purdy; Walter Bosch; Jean-Paul Bahary; Maltibehn P Patel; Matthew B Parliament; Michael I Lock; Harold Y Lau; Luis Souhami; Scot A Fisher; Young Kwok; Michael J Seider; Eric Vigneault; Seth A Rosenthal; Gary S Gustafson; Hiram A Gay; Stephanie L Pugh; Howard M Sandler; Benjamin Movsas Journal: Int J Radiat Oncol Biol Phys Date: 2022-01-01 Impact factor: 7.038
Authors: C E Olsson; D Alsadius; N Pettersson; S L Tucker; U Wilderäng; K-A Johansson; G Steineck Journal: Br J Cancer Date: 2015-08-04 Impact factor: 7.640